Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Solon Eiendom ASA : Segment revenue increased 25 % compared to same quarter last year

Solon Eiendom ASA
Posted on: 09 Nov 17

(Oslo, Norway, 09 November 2017) Solon Eiendom ASA (OSE:SOLON) will present the Q3 2017 report at 08.30 am CET at KS Agenda, Haakon VIIs gate 9, Oslo.

Key financials year to date Q3 2017 (year to date Q3 2016 in brackets):

  • Total sales value of NOK 1277 (652) million
  • Total segment revenue of NOK 775 (556) million
  • Total segment EBITDA of NOK 148 (102) million

Key financials Q3 2017 (Q3 2016 in brackets):

  • Total segment revenue of NOK 248 (198) million
  • Total segment EBITDA of NOK 47 (44) million
  • Total sales value of NOK 185 (230) million
  • Project margin (including finance) of 25 % (26 %)
  • 305 (266) units under construction at September 30, with 87 % (73 %) of these sold
  • 99 % of expected completions in 2017 and 86 % of expected completions in 2018 are sold

The quarterly presentation materials is enclosed and will be available on the company's web site, www.soloneiendom.no and www.newsweb.no.

For further information, please contact:
Andreas Martinussen, Chief Executive Officer, Solon Eiendom ASA
Telephone:     +47 400 00 405, email:  am@soloneiendom.no

Scott Danielsen, Chief Financial Officer, Solon Eiendom ASA
Telephone:     +47 952 55 620, email:  sd@soloneiendom.no

About Solon Eiendom ASA
Solon Eiendom is a Norwegian residential real estate development company focusing on the Oslo and Akershus region.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

SEA20171109_SolonEiendom_Quarterly_report
SEA20171109_SolonEiendom_Presentation
SEA20171109_Q3_2017_Solon Eiendom


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Solon Eiendom ASA via GlobeNewswire
HUG#2148301
GlobeNewswire
globenewswire.com

Last updated on: 10/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.